Evidence map›Paper›PMID 40447777›Full record

ArticleScientific reports2025

Personalized medication recommendations for Parkinson's disease patients using gated recurrent units and SHAP interpretability.

Atiye Riasi, Mehdi Delrobaei, Mehri Salari

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Atiye RiasiDepartment of Biomedical Engineering, Faculty of Electrical Engineering, K. N. Toosi University of Technology, Tehran, Iran.
Mehdi DelrobaeiDepartment of Mechatronics, Faculty of Electrical Engineering, K. N. Toosi University of Technology, Tehran, Iran. delrobaei@kntu.ac.ir.
Mehri SalariMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing Parkinson's disease (PD) through medication can be challenging due to varying symptoms and disease duration. This study aims to demonstrate the potential of sequence-by-sequence algorithms in recommending personalized medication combinations for patients with PD based on their previous visits. Our proposed method employs a gated recurrent unit model to predict accurate combinations of critical medication types for PD based on each patient's motor symptoms and prescribed medication from previous visits. We built a multi-label model with gated recurrent units on two data architectures: (1) personalized input using each patient's previous visits as a sample and (2) non-personalized input treating each visit as an independent sample. The 10-fold cross-validation results showed that the personalized architecture model outperforms the non-personalized model in accuracy (0.92), precision (0.94), recall (0.94), F1-score (0.94), Hamming loss (0.03), and macro average area under the receiver operating characteristic (0.94). To interpret the model's predictions, we employed SHapley Additive exPlanations (SHAP) values, which provide insights into the importance of variables both globally (across the entire model) and at the individual patient level. The results contribute to the sequential-based decision support system potentially enhancing the remote management of PD pharmacologic issues.

Indexed as

Antiparkinson AgentsParkinson DiseasePrecision MedicineAgedAlgorithmsFemaleHumansMaleMiddle AgedROC CurveAntiparkinson AgentsDecision support systemsExplainable artificial intelligencePersonalized decisionsPharmacological decisionsSequential learning

Identifiers

PMID40447777
PMCPMC12125215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.